CSIMarket
 
Morphosys Ag  (MOR)
Other Ticker:  
 
 
Price: $17.8400 $-0.10 -0.557%
Day's High: $18.02 Week Perf: -0.28 %
Day's Low: $ 17.70 30 Day Perf: 2.35 %
Volume (M): 393 52 Wk High: $ 18.31
Volume (M$): $ 7,002 52 Wk Avg: $8.42
Open: $17.88 52 Wk Low: $3.74



 Market Capitalization (Millions $) 612
 Shares Outstanding (Millions) 34
 Employees 434
 Revenues (TTM) (Millions $) 267
 Net Income (TTM) (Millions $) -213
 Cash Flow (TTM) (Millions $) 451
 Capital Exp. (TTM) (Millions $) 0

Morphosys Ag
Morphosys AG is a German biotechnology company focused on the development of therapeutic antibodies for the treatment of cancer and other diseases. Founded in 1992, the company has its headquarters in Planegg near Munich in Germany.

Morphosys AG's core technology is based on its proprietary antibody platform called "HuCAL" (Human Combinatorial Antibody Library). This technology enables the generation of fully human monoclonal antibodies that can target specific disease targets with high affinity and specificity. The antibodies can be optimized for different applications, such as cancer treatment or autoimmune diseases, using its proprietary "Ylanthia" antibody library.

Morphosys has a strong pipeline of therapeutic antibodies in various phases of development. Its lead product candidate, MOR208, is a monoclonal antibody targeting CD19, a protein expressed on the surface of B cells. The drug is currently in phase 3 clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one of the most common types of non-Hodgkin's lymphoma. Another drug candidate, MOR202, targets CD38, a protein found on the surface of multiple myeloma cells. The drug is currently in phase 2 clinical trials.

Morphosys has partnerships with several major pharmaceutical companies, including Johnson & Johnson, Bayer AG, Novartis AG, and Roche Holding AG. These partnerships provide the company with access to funding, expertise, and technology, as well as the potential for future milestone payments and royalties.

Morphosys has a global presence, with offices and research facilities in the United States, Japan, and Europe. The company has a strong commitment to corporate social responsibility, with initiatives focused on sustainability, patient welfare, and diversity and inclusion.

In summary, Morphosys AG is a leading biotechnology company focused on the development of therapeutic antibodies for the treatment of cancer and other diseases. The company's proprietary technology, strong pipeline, and partnerships with major pharmaceutical companies position it well for future growth and success in the biotech industry.


   Company Address: Semmelweisstrasse 7 Planegg 82152
   Company Phone Number: 89-89927-0   Stock Exchange / Ticker: NASDAQ MOR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Morphosys Ag

Morphosys Ag Faces Growing Losses in Fourth Quarter Earnings Report

The stock market has been closely following the fourth quarter earnings season of Morphosys Ag, and the results have been met with mixed reactions. The company reported a significant increase in deficit per share, with a staggering $-6.19 per share compared to $-4.95 a year ago and $0.00 per share in the previous quarter. This news has undoubtedly raised concerns among investors and analysts alike.
Additionally, the revenue for Morphosys Ag took a hit, decreasing by -14.371% to $266.87 million from $311.66 million in the same quarter last year and sequentially from $0.00 million. This decline in revenue further adds to the challenges facing the company in the current market environment.






 

Morphosys Ag's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Morphosys Ag does not provide revenue guidance.

Earnings Outlook
Morphosys Ag does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com